Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Innovation Pharmaceuticals stock

IPIX
US45782D1000
A2DTBJ

Price

0
Today +/-
-0
Today %
-0 %
P

Innovation Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Innovation Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Innovation Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Innovation Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Innovation Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Innovation Pharmaceuticals Stock Price History

DateInnovation Pharmaceuticals Price
10/1/20240 undefined
9/30/20240 undefined
9/27/20240 undefined
9/26/20240 undefined
9/25/20240 undefined
9/24/20240 undefined
9/23/20240 undefined
9/20/20240 undefined
9/19/20240 undefined
9/18/20240 undefined
9/17/20240 undefined
9/16/20240 undefined
9/13/20240 undefined
9/12/20240 undefined
9/11/20240 undefined
9/10/20240 undefined
9/9/20240 undefined
9/6/20240 undefined
9/4/20240 undefined

Innovation Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Innovation Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Innovation Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Innovation Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Innovation Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Innovation Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Innovation Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Innovation Pharmaceuticals’s growth potential.

Innovation Pharmaceuticals Revenue, EBIT and net profit per share

DateInnovation Pharmaceuticals RevenueInnovation Pharmaceuticals EBITInnovation Pharmaceuticals Net Income
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined

Innovation Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200620072008200920102011201220132014201520162017201820192020202120222023
000000000000000000
------------------
------------------
000000000000000000
000-1-3-5-4-2-8-12-12-15-13-6-4-9-6-2
------------------
000-1-3-5-4-3-10-13-12-15-16-8-6-13-7-3
----200.0066.67-20.00-25.00233.3330.00-7.6925.006.67-50.00-25.00116.67-46.15-57.14
9.339.7352.3791.8491.8690.390.1694.98105.04115.09119.91127.29144.51178.23237.3386.16503.87505.77
------------------
Details

Keystats

ⓘ

Revenue and Growth

The Innovation Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Innovation Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (k)DEBT (M)TOTAL CAPITAL (M)
200620072008200920102011201220132014201520162017201820192020202120222023
                                   
0.010.010.350.1400.070.032.964.998.416.314.142.50.586.0210.193.811.52
000000000000000000
000000000000000000
000000000000000000
001002010040010570347272308984692495145116
0.010.010.450.160.10.110.032.975.568.766.584.452.60.636.1110.693.951.63
1010000000403890120210000
00000000000000003.983.81
000000000000000000
0.010.01000000.014.965.024.314.213.783.343.062.752.312
000000000000000000
00000000300494436305159787885613778
0.020.02000000.015.35.554.844.643.943.423.143.616.435.88
0.030.030.450.160.10.110.032.9810.8614.3111.429.096.544.059.2514.310.387.52
                                   
0010101010101010121214172133445152
0.050.10.150.20.634.849.2314.8729.2248.1856.9768.383.7590.54102.82124.84129.09129.57
-0.03-0.08-0.52-2.01-5.44-11.38-16.34-19.77-28.02-41.17-54.02-69.55-85.92-94.6-101.24-115.12-122.16-125.33
000000000000000000
000000000000000000
0.020.02-0.36-1.8-4.8-6.53-7.1-4.891.217.022.96-1.24-2.15-4.041.619.766.984.29
000.010.341.192.141.971.852.661.843.534.73.192.132.042.562.572.99
000.371.182.252.463.394.273.563.442.933.863.493.253.432.521.991.82
000000001.4000000.131.51.551.49
000.030.431.472.172.022.022.022.022.022.022.021.921.91.460.250.21
00000000000000016519755
000.411.954.916.777.388.149.647.38.4810.588.697.37.58.26.566.57
0040000350000000087900786457
000000000000000000
000004802800000000417252550
0040000830280000000879417252841457
000.811.954.917.67.668.149.647.38.4810.588.698.177.928.467.47.02
0.020.020.450.150.111.070.563.2510.8514.3211.449.336.544.149.5218.2214.3811.32
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Innovation Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Innovation Pharmaceuticals's financial health and stability.

Assets

Innovation Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Innovation Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Innovation Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Innovation Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200620072008200920102011201220132014201520162017201820192020202120222023
000-1-3-5-4-3-8-13-12-15-16-8-6-13-7-3
000000000000000000
000000000000000000
000111100012-1-10000
000003300011432400
000000000000000000
000000000000000000
0000-100-1-7-13-9-11-13-6-4-9-6-2
00000000-2000000000
00000000-20000000-40
0000000000000000-40
000000000000000000
0000000000000000-10
0000001512168911491350
0000000412168911491330
------------------
000000000000000000
0000000223-2-2-1-154-6-2
-0.01-0.01-0.08-0.21-1.11-0.74-0.69-1.92-10.18-13.53-10.3-12.05-13.4-6.42-4.25-9.57-6.36-2.17
000000000000000000

Innovation Pharmaceuticals stock margins

The Innovation Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Innovation Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Innovation Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Innovation Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Innovation Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Innovation Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Innovation Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Innovation Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Innovation Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Innovation Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Innovation Pharmaceuticals Margin History

Innovation Pharmaceuticals Gross marginInnovation Pharmaceuticals Profit marginInnovation Pharmaceuticals EBIT marginInnovation Pharmaceuticals Profit margin
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %
20060 %0 %0 %

Innovation Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Innovation Pharmaceuticals earnings per share therefore indicates how much revenue Innovation Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Innovation Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Innovation Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Innovation Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Innovation Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Innovation Pharmaceuticals Revenue, EBIT and net profit per share

DateInnovation Pharmaceuticals Sales per ShareInnovation Pharmaceuticals EBIT per shareInnovation Pharmaceuticals Earnings per Share
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined

Innovation Pharmaceuticals business model

Innovation Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of novel therapeutics in various areas of medicine. Founded in 2007 as Cellceutix Corporation, the company was renamed Innovation Pharmaceuticals Inc. in 2016. The goal of Innovation Pharmaceuticals is to meet the needs of patients suffering from rare or severe diseases by developing innovative therapies. The focus is on combating inflammation, infections, and cancer. The company's business model is to guide compounds through the stages of clinical development and then license or sell them to large pharmaceutical companies. The different divisions of Innovation Pharmaceuticals are diverse and encompass dermatology, oncology, and infectious diseases, among others. The company has a pipeline of products currently in clinical trials or nearing entry into the clinical phase. One of Innovation Pharmaceuticals' leading products is Brilacidin, a synthetic peptide that can be used as a broad-spectrum antibiotic as well as a potential drug for the treatment of inflammation and cancer. Brilacidin has shown promising results in clinical studies and is currently being investigated in various indications. Another promising product of Innovation Pharmaceuticals is Kevetrin, a drug used for the treatment of cancer. Kevetrin is unique as it focuses on the p53 tumor suppression mechanism. Kevetrin is currently in the clinical phase of development, and Innovation Pharmaceuticals has begun to explore its use in various types of cancer. Innovation Pharmaceuticals also has an extensive portfolio of compounds and technologies in the preclinical stage. These compounds have the potential to create new therapeutic options for various diseases, including autoimmune diseases, chronic inflammatory diseases, and infectious diseases. In summary, Innovation Pharmaceuticals Inc. is a leading biopharmaceutical company focusing on the development of innovative therapeutics in various areas of medicine. The company has an impressive pipeline of products and technologies at various stages of development that have shown promising results. Innovation Pharmaceuticals has the potential to significantly improve the lives of patients with rare and severe diseases by developing novel therapies that are currently unavailable. Innovation Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Innovation Pharmaceuticals SWOT Analysis

Strengths

Innovation Pharmaceuticals Inc has a strong intellectual property portfolio, including patents and trademarks, which provides a competitive advantage in the pharmaceutical industry.

The company's research and development capabilities are advanced, allowing for the discovery and development of innovative drugs.

Innovation Pharmaceuticals Inc has a dedicated team of highly skilled scientists and researchers who have expertise in various therapeutic areas.

Weaknesses

The company is heavily dependent on external funding sources for its research and development activities, which may pose financial risks and limitations.

Innovation Pharmaceuticals Inc currently has a limited product pipeline, with only a few drug candidates in various stages of development.

The company's market penetration is relatively low, limiting its ability to generate significant revenues and market share.

Opportunities

The increasing demand for novel and effective drugs in the pharmaceutical market provides an opportunity for Innovation Pharmaceuticals Inc to capture market share with its innovative drug candidates.

The company can explore potential collaborations and partnerships with pharmaceutical giants to leverage their resources and distribution networks for commercializing its products.

Expansion into emerging markets and the exploration of untapped therapeutic areas could provide new growth opportunities for the company.

Threats

Intense competition from established pharmaceutical companies and generic drug manufacturers poses a threat to Innovation Pharmaceuticals Inc's market position and profitability.

Regulatory approvals and compliance requirements can be time-consuming and expensive, potentially delaying the commercialization of the company's drug candidates.

Economic downturns and changes in healthcare policies could affect market demand for pharmaceutical products and potentially impact the company's financial performance.

Innovation Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Innovation Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Innovation Pharmaceuticals shares outstanding

The number of shares was Innovation Pharmaceuticals in 2023 — This indicates how many shares 505.768 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Innovation Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Innovation Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Innovation Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Innovation Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Innovation Pharmaceuticals.

Innovation Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
8.62583 % Kips Bay Select LP44,712,000-320,6599/28/2023
0.53098 % Ehrlich (Leo)2,752,31009/28/2023
0.14469 % Schechter (Barry Alan M.D.)750,00009/28/2023
0.10128 % Spektor (Zorik M.D.)525,00009/28/2023
0.04715 % Harness (Jane A)244,41709/28/2023
0.01464 % Able Wealth Management LLC75,89475,89412/31/2023
0.00212 % Kingfisher Capital LLC11,000012/31/2023
0 % CAPTRUST Financial Advisors0-5,1509/30/2022
1

Innovation Pharmaceuticals Executives and Management Board

Mr. Leo Ehrlich65
Innovation Pharmaceuticals Chairman of the Board, Chief Executive Officer, Chief Financial Officer
Compensation 565,850
Ms. Jane Harness54
Innovation Pharmaceuticals Senior Vice President - Clinical Sciences and Portfolio Management
Compensation 275,000
1

Most common questions regarding Innovation Pharmaceuticals

What values and corporate philosophy does Innovation Pharmaceuticals represent?

Innovation Pharmaceuticals Inc represents values of innovation, progress, and growth in the pharmaceutical industry. The company's corporate philosophy revolves around developing novel and effective therapies to improve patients' lives. With a focus on research and development, Innovation Pharmaceuticals Inc strives to discover and advance breakthrough treatments for various diseases and medical conditions. This commitment to innovation and the pursuit of new solutions sets the company apart in the pharmaceutical sector. With a strong emphasis on scientific excellence, Innovation Pharmaceuticals Inc aims to make a positive impact on global healthcare.

In which countries and regions is Innovation Pharmaceuticals primarily present?

Innovation Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Innovation Pharmaceuticals achieved?

Innovation Pharmaceuticals Inc, a leading pharmaceutical company, has achieved several significant milestones. Firstly, the company successfully completed phase 2 clinical trials for its flagship drug candidate, Brilacidin, which exhibited promising results in treating oral mucositis, a severe condition affecting cancer patients. Additionally, Innovation Pharmaceuticals Inc has obtained patents for Brilacidin in various countries, ensuring its market exclusivity. The company also established collaborations with prestigious research institutions and renowned healthcare organizations to advance its pipeline. With these accomplishments, Innovation Pharmaceuticals Inc has positioned itself as a key player in the pharmaceutical industry, revolutionizing patient care and offering hope for a better future.

What is the history and background of the company Innovation Pharmaceuticals?

Innovation Pharmaceuticals Inc. (Company) is a pharmaceutical company focused on the discovery and development of innovative therapies for various diseases. Established in [year], the company has built a strong foundation in research, working towards advancing treatment options for conditions such as cancer, autoimmune disorders, and antibiotic-resistant infections. With a team of dedicated scientists and industry experts, Innovation Pharmaceuticals Inc. strives to make a positive impact on healthcare worldwide. The company's commitment to innovation and scientific excellence has positioned them as a leading player in the pharmaceutical industry, continually aiming to improve patient outcomes through groundbreaking therapeutics.

Who are the main competitors of Innovation Pharmaceuticals in the market?

The main competitors of Innovation Pharmaceuticals Inc in the market include biopharmaceutical companies such as Pfizer Inc., Johnson & Johnson, Novartis AG, and Merck & Co., Inc.

In which industries is Innovation Pharmaceuticals primarily active?

Innovation Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Innovation Pharmaceuticals?

The business model of Innovation Pharmaceuticals Inc. focuses on the development and commercialization of innovative drug therapies. Through extensive research and collaboration with scientific experts, the company aims to discover and bring to market novel treatments for various diseases and medical conditions. Leveraging its expertise in pharmaceuticals, Innovation Pharmaceuticals Inc. seeks to improve patients' lives by advancing cutting-edge drug candidates and conducting clinical trials to demonstrate their efficacy and safety. This commitment to innovation and medical breakthroughs drives the company's business strategy and growth.

What is the P/E ratio of Innovation Pharmaceuticals 2024?

The P/E ratio cannot be calculated for Innovation Pharmaceuticals at the moment.

What is the P/S ratio of Innovation Pharmaceuticals 2024?

The P/S cannot be calculated for Innovation Pharmaceuticals currently.

What is the AlleAktien quality score of Innovation Pharmaceuticals?

The AlleAktien quality score for Innovation Pharmaceuticals is 2/10.

What is the revenue of Innovation Pharmaceuticals 2024?

The revenue cannot currently be calculated for Innovation Pharmaceuticals.

How high is the profit of Innovation Pharmaceuticals 2024?

The profit cannot currently be calculated for Innovation Pharmaceuticals.

What is the business model of Innovation Pharmaceuticals

Innovation Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching, developing, and marketing new therapeutics for the treatment of serious diseases. The company serves several areas, including oncology and dermatology. It is listed on the NASDAQ stock exchange under the ticker "IPIX" and has its headquarters in Beverly, Massachusetts. The core business of Innovation Pharmaceuticals Inc is to discover and develop new drugs and therapies to meet the needs of patients with serious illnesses. The company has an extensive pipeline of several products tailored to various medical needs. For example, Brilacidin, the company's flagship product, is an innovative drug developed for the treatment of skin and soft tissue infections. The company has also completed a phase III clinical trial for Brilacidin to treat oral mucositis in cancer patients and plans to submit an application for approval to the FDA. In addition to Brilacidin, Innovation Pharmaceuticals Inc is also developing other products. The company is working on a new drug for the treatment of thyroid carcinomas as well as a drug for the treatment of cystic fibrosis. Furthermore, the company has a wide range of patents and intellectual property related to the discovery and development of new therapeutics. To sell its products in the market, Innovation Pharmaceuticals Inc hopes for reliable collaboration with various companies that can market their products. The company has entered into an agreement with Alfasigma USA, Inc. for the sale of Brilacidin for topical use in skin and soft tissue infections in North America. A similar agreement with another company may also be pursued for the distribution of Brilacidin in other regions. In addition to direct marketing of its products and partnerships with other companies, Innovation Pharmaceuticals Inc also relies on collaboration with scientists, universities, and research institutions. The company believes in an open innovation strategy that allows for collaboration with other companies and research institutions to accelerate progress in drug development. Collaboration has led to several successful collaborations and partnerships in the medical field, earning Innovation Pharmaceuticals Inc a good reputation in the industry. Innovation Pharmaceuticals Inc is an emerging biopharmaceutical company that focuses on developing new and innovative therapeutics to combat serious diseases. The company has an extensive pipeline of product candidates for various medical areas and is actively working on marketing its products and collaborating with other companies and research institutions. With a strong focus on innovation in drug development, Innovation Pharmaceuticals Inc is well positioned to achieve further notable successes in the industry in the future.

What is the Innovation Pharmaceuticals dividend?

Innovation Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Innovation Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Innovation Pharmaceuticals or the company does not pay out a dividend.

What is the Innovation Pharmaceuticals ISIN?

The ISIN of Innovation Pharmaceuticals is US45782D1000.

What is the Innovation Pharmaceuticals WKN?

The WKN of Innovation Pharmaceuticals is A2DTBJ.

What is the Innovation Pharmaceuticals ticker?

The ticker of Innovation Pharmaceuticals is IPIX.

How much dividend does Innovation Pharmaceuticals pay?

Over the past 12 months, Innovation Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Innovation Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Innovation Pharmaceuticals?

The current dividend yield of Innovation Pharmaceuticals is .

When does Innovation Pharmaceuticals pay dividends?

Innovation Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Innovation Pharmaceuticals?

Innovation Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Innovation Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Innovation Pharmaceuticals located?

Innovation Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Innovation Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Innovation Pharmaceuticals from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Innovation Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Innovation Pharmaceuticals in the year 2023?

In the year 2023, Innovation Pharmaceuticals distributed 0 USD as dividends.

In which currency does Innovation Pharmaceuticals pay out the dividend?

The dividends of Innovation Pharmaceuticals are distributed in USD.

All fundamentals about Innovation Pharmaceuticals

Our stock analysis for Innovation Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innovation Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.